Relapsed Malignant Mesothelioma Clinical Trial
Official title:
A Phase 1 Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, Administered With a Fixed Dose of VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Relapsed Malignant Mesothelioma
| Verified date | January 2017 |
| Source | Verastem, Inc. |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this study is to evaluate rising dose levels of VS-5584 administered in combination with a fixed dose of VS-6063 in subjects with relapsed malignant mesothelioma to determine a recommended Phase 2 dose (RP2D) for further development of this combination in this indication.
| Status | Terminated |
| Enrollment | 21 |
| Est. completion date | October 2015 |
| Est. primary completion date | October 2015 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: 1. Histopathologically-confirmed diagnosis of malignant mesothelioma (pleural or peritoneal). Must have disease that has relapsed following at least one prior line of chemotherapy. 2. Must have received at least 3 cycles of first-line chemotherapy. 3. Evaluable or measurable disease as assessed by Response Evaluation Criteria in Solid Tumors (RECIST). 4. Must have archival tumor tissue available for biomarker analysis. A study-specific tumor core biopsy, pleural effusion or ascites sample must be obtained prior to treatment if archival tissue is not available. 5. Performance status according to the Karnofsky Performance Scale =70%. 6. Fasting blood glucose of = 140 mg/dL (7.8 mmol/L). 7. Adequate renal function (creatinine = 1.5x upper limit of normal [ULN]) and/or glomerular filtration rate (GFR) of =50 mL/min. 8. Adequate hepatic function (total bilirubin = 1.5x ULN; AST and ALT = 3x ULN). 9. Adequate bone marrow function (hemoglobin =9.0 g/dL; platelets =100 x10^9 cells/L; absolute neutrophil count =1.5x10^9 cells/L) without the use of hematopoietic growth factors. Exclusion Criteria: 1. Have had a previous extra pleural pneumonectomy (EPP). 2. Gastrointestinal condition which could interfere with the swallowing or absorption of study drug. 3. Uncontrolled or severe concurrent medical condition (including uncontrolled brain metastases). 4. Known history of stroke or cerebrovascular accident within 6 months prior to the first dose of study drug. 5. Any evidence of serious active infection. 6. Undergoing active treatment for a secondary malignancy. 7. Cancer-directed therapy (chemotherapy, radiotherapy) within 21 days of the first dose of study drug or 5 half-lives, whichever is shorter. 8. Major surgery within 28 days prior to the first dose of study drug. 9. Acute or chronic pancreatitis. 10. Diabetes mellitus requiring insulin treatment or subjects with a hemoglobin A1C (HbA1C) >7%. 11. History or evidence of cardiac risk. 12. Known history of malignant hypertension. |
| Country | Name | City | State |
|---|---|---|---|
| United Kingdom | University of Leicester | Leicester | |
| United Kingdom | The Institute of Cancer Research | Sutton Surrey | |
| United States | The University of Chicago Medical Center | Chicago | Illinois |
| United States | Memorial Sloane Kettering Cancer Center | New York | New York |
| Lead Sponsor | Collaborator |
|---|---|
| Verastem, Inc. |
United States, United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Incidence of dose-limiting toxicities (DLTs) | Dose Escalation Phase: Frequency of DLTs at each dose level associated with administration of VS-5584 and VS-6063 in a 21 day cycle | 6 months | |
| Primary | Safety and tolerability of the combination of VS-5584 and VS-6063 | Dose Escalation Phase and Expansion Phase: A composite by dose level to include incidence of AEs, SAEs (overall and severity), laboratory abnormalities, ECGs, vital signs, Karnofsky Performance Status, dose interruptions and dose reductions as a measure of safety and tolerability | 16 months | |
| Secondary | Pharmacokinetics of VS-5584 & VS-6063 maximum observed plasma concentration (Cmax) | 0-48 hours per patient | ||
| Secondary | Pharmacokinetics of VS-5584 & VS-6063 plasma area under the curve from time zero to last quantifiable concentration (AUClast) | 0-48 hours per patient | ||
| Secondary | Pharmacokinetics of VS-5584 & VS-6063 time to reach maximum observed concentration (Tmax) | 0-48 hours per patient | ||
| Secondary | Pharmacokinetics of VS-5584 & VS-6063 area under the curve from time zero to extrapolated infinite time (AUCO-inf) | 0-48 hours per patient | ||
| Secondary | Pharmacokinetics of VS-5584 & VS-6063 apparent oral clearance (CL/F) | 0-48 hours per patient | ||
| Secondary | Pharmacokinetics of VS-5584 & VS-6063 apparent volume of distribution (Vz/F) | 0-48 hours per patient | ||
| Secondary | Pharmacokinetics of VS-5584 & VS-6063 trough plasma concentration | 0-48 hours per patient |